Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis
| Autor: | Li Qiong Hao, Chang Chuan Pan, Li Li Luo, Ting Wang, Jing Rui Yu, Xu De Yin, Yu Long, Xiao Hong Cai |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Antimetabolites Antineoplastic medicine.medical_specialty Guanine Lung Neoplasms medicine.medical_treatment Gene Expression lcsh:Medicine Pemetrexed Disease-Free Survival Glutamates Carcinoma Non-Small-Cell Lung Internal medicine Odds Ratio medicine Humans Progression-free survival Lung cancer lcsh:Science Neoplasm Staging Chemotherapy Multidisciplinary business.industry Hazard ratio lcsh:R Thymidylate Synthase Odds ratio medicine.disease Databases Bibliographic Clinical trial Regimen Treatment Outcome lcsh:Q business Research Article medicine.drug |
| Zdroj: | PLoS ONE, Vol 8, Iss 9, p e74284 (2013) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | BACKGROUND: The predictive value of thymidylate synthase (TYMS) to sensitivity to pemetrexed-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients is controversial. We conducted a meta-analysis of all relevant published data to assess the association of TYMS expression with the clinical outcomes of pemetrexed-based regimen in advanced NSCLC. PATIENTS AND METHODS: We conducted an electronic search using using PubMed, Embase, OVID and Cochrane Library databases and manual search. Pooled odds ratio (OR) for the response rate and hazard ratio (HR) for the overall survival and progression free survival were calculated using the software Revman 5.0. RESULTS: There were 11 studies (n=798) met our criteria for evaluation. Response rate to pemetrexed-based regimen was significantly higher in patients with low/negative TYMS (OR=2.96, 95%CI [1.81, 4.86] P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|